Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Evaluation of Spectral Cardiac CT for the Diagnosis of Acute Myocarditis

Condition:   Patients With Suspected Acute Myocarditis
Intervention:   Procedure: Spectral cardiac CT scan
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified September 2016

MOMENTUM 3 Continued Access Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Intervention:   Device: HeartMate 3 LVAS
Sponsors:   St. Jude Medical;   Thoratec, LLC
Recruiting - verified September 2016

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Conditions:   Cardiomyopathy, Hypertrophic;   Cardiomyopathy, Hypertrophic, Familial
Intervention:   Drug: Perhexiline
Sponsor:   Heart Metabolics Limited
Recruiting - verified September 2016

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Condition:   Cardiomyopathy, Hypertrophic Obstructive
Intervention:   Drug: MYK-461
Sponsor:   MyoKardia, Inc.
Recruiting - verified August 2016

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Condition:   Heart Failure
Interventions:   Drug: ivabradine;   Other: Usual Care
Sponsors:   Duke University;   Amgen
Recruiting - verified July 2016

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis meglumine
Sponsor:   Pfizer
Recruiting - verified September 2016

Carpal Tunnel Syndrome and Amyloid Cardiomyopathy

Conditions:   Amyloidosis;   Cardiomyopathy;   Transthyretin Amyloidosis;   Senile Systemic Amyloidosis;   Carpal Tunnel Syndrome
Intervention:  
Sponsor:   The Cleveland Clinic
Recruiting - verified April 2016

Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy

Condition:   Fabry Disease
Intervention:  
Sponsor:   Ulla Feldt-Rasmussen
Enrolling by invitation - verified September 2016

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Conditions:   Mild Tricuspid Regurgitation;   Moderate Tricuspid Regurgitation;   Tricuspid Regurgitation
Interventions:   Procedure: TV Annuloplasty;   Procedure: MVS Alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   German Society for Thoracic and Cardiovascular Surgery
Recruiting - verified September 2016

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Condition:   Aortic Valve Stenosis
Interventions:   Device: SAPIEN 3 THV;   Biological: Optimal Heart Failure Therapy
Sponsors:   Cardiovascular Research Foundation, New York;   Cardialysis BV;   Boston Biomedical Associates LLC
Recruiting - verified September 2016

Molecular Imaging of Primary Amyloid Cardiomyopathy

Conditions:   Amyloidosis, Primary;   Cardiomyopathy
Interventions:   Radiation: F-18 florbetapir/C-11 acetate PET;   Device: MRI
Sponsors:   Brigham and Women's Hospital;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   American Heart Association
Recruiting - verified June 2016

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

Condition:   Ischemic Cardiomyopathy
Interventions:   Biological: Mesenchymal Stem Cells (MSC);   Biological: Cardiac Stem Cells (CSC);   Biological: Placebo (Plasmalyte A)
Sponsors:   The University of Texas Health Science Center, Houston;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2016

Group Medical Visits in Heart Failure

Condition:   Heart Failure
Intervention:   Behavioral: Group medical visits
Sponsor:   VA Office of Research and Development
Recruiting - verified September 2016

Individualized Early Risk Assessment for Heart Diseases

Conditions:   Cardiomyopathy, Hypertrophic;   Cardiomyopathy, Dilated
Intervention:   Other: Skin biopsy, genotyping and disease phenotyping
Sponsor:   Universitätsklinikum Hamburg-Eppendorf
Recruiting - verified September 2016

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Conditions:   Heart Failure;   Cardiomyopathy;   Ventricular Dysfunction
Interventions:   Biological: MPC Intramyocardial Injection;   Drug: Control Solution
Sponsors:   Annetine Gelijns;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2016

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461

Condition:   Hypertrophic Cardiomyopathy
Intervention:   Drug: MYK-461
Sponsor:   MyoKardia, Inc.
Completed - verified September 2016

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Condition:   Primary Systemic (AL) Amyloidosis
Interventions:   Drug: NEOD001;   Other: Placebo
Sponsor:   Prothena Therapeutics Ltd.
Recruiting - verified September 2016

Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome

Conditions:   Brugada Syndrome;   Arrhythmogenic Right Ventricular Cardiomyopathy
Intervention:   Drug: flecainide iv
Sponsor:   New York University School of Medicine
Recruiting - verified September 2016

Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System

Condition:   Mitral Valve Regurgitation
Intervention:   Device: Mitral valve replacement
Sponsor:   Neovasc Inc.
Recruiting - verified September 2016

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.

Conditions:   Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency;   Carnitine-acylcarnitine Translocase (CACT) Deficiency
Intervention:   Drug: UX007
Sponsor:   Ultragenyx Pharmaceutical Inc
Enrolling by invitation - verified September 2016

TAKO-TSUBO Cardiomyopathy and Genetic

Conditions:   Tako-TSUBO Cardiomyopathy;   Acute Coronary Syndrome
Intervention:  
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Fédération Française de Cardiologie
Completed - verified February 2016

Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism

Conditions:   Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency Disease;   ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of;   Barth Syndrome
Intervention:   Drug: triheptanoin
Sponsors:   University of Pittsburgh;   Ultragenyx Pharmaceutical Inc
Available - verified September 2016

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Condition:   Non-ischemic Dilated Cardiomyopathy
Interventions:   Procedure: Transendocardial injection;   Biological: Autologous hMSCs;   Biological: Allogeneic hMSCs
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified September 2016

Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis

Conditions:   Hypertrophic Cardiomyopathy;   Acute Coronary Syndrome
Intervention:   Radiation: 99mTc-NC100692
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified September 2016

Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease

Conditions:   Acute Myocardial Infarction;   Ischemic Cardiomyopathy;   Dilated Cardiomyopathy;   Heart Failure
Intervention:   Biological: autologous bone marrow-derived cells
Sponsor:   Johann Wolfgang Goethe University Hospital
Active, not recruiting - verified September 2016